Secuado

Active Ingredient(s): Asenapine
FDA Approved: * October 11, 2019
Pharm Company: * HISAMITSU
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Secuado Overview

Asenapine, sold under the trade names Saphris and Sycrest among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder. It was chemically derived via altering the chemical structure of the tetracyclic (atypical) antidepressant, mianserin.[5] Contents 1 Medical uses 1.1 Schizophrenia 1.2 Acute mania 2 Adverse effects 2.1 Discontinuation 3 Pharmacology 3.1 Pharmacodynamics 4 History 5 References ...

Read more Secuado Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Asenapine

Recent Secuado Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Secuado: (3 results)

Sorted by National Drug Code

• 68968-0172 Secuado 3.8 mg/D Transdermal Film, Extended Release by Noven Therapeutics, LLC
• 68968-0173 Secuado 5.7 mg/D Transdermal Film, Extended Release by Noven Therapeutics, LLC
• 68968-0174 Secuado 7.6 mg/D Transdermal Film, Extended Release by Noven Therapeutics, LLC

Other drugs which contain Asenapine or a similar ingredient: (2 results)

• ASENAPINE
• SAPHRIS Asenapine20 discussions